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ABSTRACT
Background: Neuropsychiatric Symptoms (NPS) are ubiquitous in dementia and are often treated
pharmacologically. The objectives of this study were to describe the use of psychotropic, anti-cholinergic,
and deliriogenic medications and to identify the prevalence of polypharmacy and psychotropic polypharmacy,
among older hospitalized patients in Ireland, with and without dementia.
Methods: All older patients (≥ 70 years old) that had elective or emergency admissions to six Irish study
hospitals were eligible for inclusion in a longitudinal observational study. Of 676 eligible patients, 598 patients
were recruited and diagnosed as having dementia, or not, by medical experts. These 598 patients were
assessed for delirium, medication use, co-morbidity, functional ability, and nutritional status. We conducted
a retrospective cross-sectional analysis of medication data on admission for 583/598 patients with complete
medication data, and controlled for age, sex, and co-morbidity.
Results: Of 149 patients diagnosed with dementia, only 53 had a previous diagnosis. At hospital admission,
458/583 patients experienced polypharmacy (≥ 5 medications). People with dementia (PwD) were
significantly more likely to be prescribed at least one psychotropic medication than patients without dementia
(99/147 vs. 182/436; p < 0.001). PwD were also more likely to experience psychotropic polypharmacy (≥
two psychotropics) than those without dementia (54/147 vs. 61/436; p < 0.001). There were no significant
differences in the prescribing patterns of anti-cholinergics (23/147 vs. 42/436; p = 0.18) or deliriogenics
(79/147 vs. 235/436; p = 0.62).
Conclusions: Polypharmacy and psychotropic drug use is highly prevalent in older Irish hospitalized patients,
especially in PwD. Hospital admission presents an ideal time for medication reviews in PwD.
Key words: dementia, delirium, anti-psychotics, behavioral and psychological symptoms of dementia (BPSD), neuropsychiatric symptoms (NPS)
Introduction
The number of people with dementia (PwD) is
escalating worldwide; estimates project the preval-
ence at over 131.5 million by 2050 (Alzheimer’s
Disease International, 2015). The majority will
experience Behavioral and Psychological Symp-
toms of Dementia (BPSD), also referred to as
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Neuropsychiatric Symptoms (NPS) during their
disease (Lawlor, 2002). BPSD refers to the
spectrum of distressing, non-cognitive symptoms
of dementia, ranging from wandering and agitation
to delusional and aggressive behavior (Cahill et al.,
2012). Psychotropic medications are commonly
prescribed to manage BPSD and have some
evidence to support their use (Bishara et al., 2009;
Seitz et al., 2013). For example, the CitAD
trial showed that the addition of citalopram to
a psychosocial intervention was more effective
at reducing agitation and caregiver distress in
PwD than the addition of placebo (Porsteinsson
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et al., 2014). Furthermore, treatment of BPSD
with atypical anti-psychotics has been found to
cause a small yet significant reduction in caregiver
burden (Mohamed et al., 2012). However, anti-
psychotics are known to increase the risk of stroke
and mortality in PwD (Schneider et al., 2005),
and a recent study has found that for every 26
PwD treated with haloperidol, there was one death
(Maust et al., 2015). Additionally, the DIADS-
2 trial found that sertraline was not efficacious
for the treatment of depression in PwD and
was associated with an increased risk of adverse
events (Rosenberg et al., 2010; Weintraub et al.,
2010). Guidelines generally recommend that non-
pharmacological treatments should be used as first-
line treatment of BPSD, and only when these fail
should psychotropic agents be trialed for short-
term use (Azermai et al., 2012). Despite this, the
usage of anti-psychotics and other psychotropics in
this vulnerable patient group remains unacceptably
high (Maust et al., 2016).
Polypharmacy, which is defined as the use of
five or more medications (Gnjidic et al., 2012),
is common in older people and is associated
with poorer health outcomes (Hajjar et al., 2007).
Similarly, psychotropic polypharmacy (concurrent
use of two or more psychotropic agents) increases
the risk of adverse events (Mojtabai and Olfson,
2010). Delirium super-imposed on dementia is
often drug-related and medications such as opioids
and benzodiazepines can trigger a delirium episode
in susceptible people (Clegg and Young, 2011).
Also, anti-cholinergic medications can negatively
affect cognitive and physical function in older
people and their use should be minimized in PwD
(Collamati et al., 2016).
Hospitalization in PwD is associated with
significantly poorer health outcomes (Zekry et al.,
2009). PwD are particularly vulnerable in this set-
ting, due to the challenges of illness, new medica-
tions, and unfamiliar environments/carers (Borbasi
et al., 2006). The report of the Irish National
Audit of Dementia (INAD) care in acute hospitals
found high levels of anti-psychotic prescribing in
hospitalized PwD, particularly when admitted from
nursing homes (de Siún et al., 2014). The authors
highlighted a need for regular medication review
on admission, echoed in the recently published
Irish National Dementia Strategy (Department
of Health, 2014). However, only 20 healthcare
records from each hospital were reviewed for anti-
psychotic prescribing in this audit (de Siún et al.,
2014). Furthermore, only people with an explicit
diagnosis of dementia who had a minimum length
of stay of five days were included. Therefore, it is
unclear whether this data is representative of the
majority of Irish PwD who are admitted to hospital.
The objectives of this study were to describe
the use of psychotropic, anti-cholinergic, and
deliriogenic medication among older hospitalized
patients, with and without dementia, and to identify
the prevalence of polypharmacy (≥5 medications)
and psychotropic polypharmacy (concurrent use
of ≥2 psychotropic agents) in these patient
groups. Our research question was “Are there
any differences in the patterns of prescribing
between older people (≥70 years) with and without
dementia, upon admission to six acute hospitals in
the south of Ireland, controlling for age, sex and
co-morbidity?” Our primary hypothesis was that
PwD are significantly more likely to be prescribed
psychotropics and to be exposed to psychotropic
polypharmacy than people without dementia, as
previously reported (Giron et al., 2001; Hartikainen
et al., 2003). Our secondary hypothesis was
that PwD are more likely to be prescribed
deliriogenic and anti-cholinergic medications and
to be prescribed more medications than people
without dementia; however, the evidence for this is
mixed or lacking (Schmader et al., 1998; Andersen
et al., 2011).
Methods
Study design, setting, and patients
The Cork Dementia Study has been described
in detail elsewhere (Timmons et al., 2015). In
brief, this longitudinal observational study explored
the prevalence and associations of dementia in
older patients admitted to all six acute hospitals
in County Cork, Ireland. County Cork has a
population of 519,032 which is comprised of
49.61% males, an older population (≥70 years)
of 42,382 (Central Statistics Office, 2012) and an
estimated dementia population of 4,830 (Cahill
et al., 2012). This is relatively comparable to
the proportions for the Republic of Ireland as
a whole (total population = 4,588,252; males =
49.53%; older population ≥70 years = 361,755;
and estimated dementia population = 41,720).
Eligibility criteria for this study included age
≥70 years old and elective or emergency admission
(non-day case). Recruitment occurred in each
hospital for a period of two weeks and lasted from
May 2012 to February 2013. Informed consent
was obtained for all patients. Exclusion criteria
included patient refusal or being moribund on
arrival to hospital. Patients were diagnosed with
dementia by a three-step approach, involving initial
cognitive screening utilizing the StandardizedMini-
Mental State Examination, followed by informant-
derived data utilizing the Informant Questionnaire
on Cognitive Decline in the Elderly. Finally,
Prescribing in hospitalized dementia patients 3
dementia status was established by the senior
author (ST), a consultant geriatrician, based on
all available information (i.e. cognitive testing,
informant-derived data, medical and demographic
history). Patients were also assessed for delirium,
depression, medication use, co-morbidity, func-
tional ability, and nutritional status. Data were
prospectively collected by researchers with nursing
or psychology backgrounds, after extensive training
in all assessment tools.
This present study is a retrospective cross-
sectional analysis of the original Cork Dementia
Study medication data, collected on admission.
First, the original medication data were cleaned
by the study pharmacist (KAW), using a three-
step cycle of screening, diagnosing, and editing
suspected data irregularities, for the purpose of
ensuring that incorrectly spelled or partially filled
entries could be corrected and coded accurately
(Van den Broeck et al., 2005). Second, the cleaned
medication data were coded by World Health
Organization (WHO) Anatomical Therapeutic
Chemical (ATC) classifications (WHO, 2015),
excluding emollients or nutritional supplements
without any active ingredients. Information on
strength, quantity, duration, or usage at follow-
up, were not recorded consistently so were not
coded. Patients with missing medication data were
excluded from the analysis. Finally, the coded
medication data were cleaned again and linked
at individual patient-level to the previously coded
clinical data.
The “Strengthening the Reporting of Obser-
vational Studies in Epidemiology” (STROBE)
guidelines have been followed in the conduct and
reporting of this research (Von Elm et al., 2007).
Ethical approval was obtained from the local ethics
committee (reference ECM 4 (t) 06/12/11 & ECM
3 (yy) 07/07/15).
Prescribing patterns
The primary outcome in this study was the differ-
ence in prescribing patterns between people with
and without dementia, particularly psychotropic
agents in PwD, and especially anti-psychotics. The
definition of a psychotropic varies significantly
throughout the literature; the research group,
by consensus, included anti-psychotics (N05A),
anti-depressants (N06A), anxiolytics (N05B), hyp-
notics (N05C), anti-convulsants/mood-stabilizers
(N03A), and anti-dementia drugs (N06D), as
these medication classes are used to manage
BPSD (Bishara et al., 2009). It is important
to acknowledge that anti-dementia drugs are
inevitably utilized more in PwD than people
without dementia, due to their cognitive enhancing
properties. Additionally, some studies do not
consider anti-convulsants/mood-stabilizers to be
psychotropics (Avorn et al., 1992; Patterson
et al., 2010). Therefore, we conducted sensitivity
analyses to assess the impact of more conservative
psychotropic definitions on our outcomes by
excluding the following in a step-wise manner:
1. N06D (Anti-dementia drugs),
2. N06D and N03A (Anti-dementia drugs and anti-
convulsants/mood-stabilizers).
We utilized ATC codes, but reclassified Lithium
(N05AN01) as a mood-stabilizer rather than an
anti-psychotic (Søndergård et al., 2008). We were
also interested in psychotropic polypharmacy, and
patterns of anti-psychotic prescribing in those
admitted from nursing homes. Other prescribing
patterns of interest included the 14 main ATC
anatomical groups (excluding “D- Dermatologic-
als”), levels of minor or major polypharmacy (5–
9 medications; or ≥10 medications, respectively),
deliriogenic medications and anti-cholinergics.
Deliriogenic medication definition was based on
published literature, decided upon by consensus
between the study pharmacist (KAW) and two con-
sultant geriatricians (ST, NOR) who are delirium
experts. The included deliriogenic medications
were predominantly in line with findings from a
systematic review conducted by Clegg et al. which
investigated the associations between medications
and risk of delirium (Clegg and Young, 2011).
These definitions and the associated ATC codes are
shown in Table 1.
Statistical analysis
The original data were entered into a FileMaker
Pro 11 database and subsequently exported
into Excel 2011 for ATC coding and linking,
before transferal into STATA software version
13 (StataCorp, College Station, TX, USA) for
data analysis; statistical significance at p-value
< 0.05 was assumed. Descriptive statistics were
utilized to summarize the population. Differences
in prescribing patterns between those with and
without dementia were assessed using the χ2
test (Fisher’s exact test if expected cell frequency
was <5) for categorical variables, and Student’s
t-test (normally distributed) or Mann–Whitney
U test (non-normally distributed) for continuous
variables. To control for age, sex, and co-morbidity
(Cumulative Illness Rating Scale in Geriatrics)
effects, these were entered as independent variables
into a model for each dependent variable, utilizing
multivariate linear, or logistic regression, for con-
tinuous or binary dependent variables, respectively.
Results are reported in terms of adjusted odds
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Table 1. Drug class deﬁnitions by WHO-ATC code
drug class who atc code
.........................................................................................................................................................................................................................................................................................................................
Psychotropic
Anti-psychotic N05A (except N05AN01 – Lithium)
Anti-depressant N06A
Anxiolytic N05B
Hypnotics N05C
Anti-convulsants/mood stabilizers N03A (including N05AN01 – Lithium)
Anti-dementia drugs N06D
Potentially Deliriogenic Drugs as decided a priori by consensus
Benzodiazepines N05BA, N05CD, N03AE01
Opioids N02A, N01AH, N02BE51, R05DA, R05FA
Dihydropyridines C08CA
Tricyclic anti-depressants N06AA
Anti-cholinergics (excluding inhaled/topical) A03AA, A03AB, A03B, A03CA, A03CB, A03DA,
A03DB, A03E, A04AD01
G04BD01-G04BD11, N02AG, N04A, N06AA,
Steroids (excluding inhaled/topical) H02, A14A, G01B
H2-receptor antagonists A02BA
Anti-Parkinson’s Drugs N04
Benzodiazepine-related drugs N05CF
Other drugs which may increase the risk of delirium but were not included in our a priori deliriogenic group
Anti-psychotics N05A (except N05AN01 - Lithium)
Non-steroidal anti-inflammatory drugs (NSAIDS) M01A
Anti-depressants N06A
Anti-dementia drug N06D
Anti-convulsant/mood stabilizer N03A (including N05AN01 - Lithium)
Typical versus atypical anti-psychotics
Typical anti-psychotics N05AA, N05AB, N05AC, N05AD, N05AE, N05AF,
N05AG (except N05AE04 - Zisprasidone)
Atypical anti-psychotics N05AH, N05AL, N05AX (including N05AE04 -
Zisprasidone)
WHO ATC = world health organization anatomical therapeutic chemical.
ratios (aOR) and their 95% confidence intervals
(95% CI).
Results
Study population characteristics
Of 676 patients eligible for study enrolment, 598
were recruited and had a diagnosis of dementia
or no dementia assigned (Figure 1). In total, a
quarter of patients had dementia (N = 149);
53/149 (35.5%) had a known diagnosis prior to
the study, and another 16/149 (11%) had known
cognitive impairment. Eighty patients (53.5%)
were diagnosed with dementia de-novo in the study,
29% (N = 23) of whom had moderate or severe
dementia.
Fifteen patients had missing medication data,
resulting in 583 patients (86% of all admissions)
with linked medication and clinical data. There was
no significant difference in terms of the proportion
of patients with missing medication data between
those with and without dementia (χ2 = 1.1; p-value
= 0.29). Just under half of the study population
were male (49%; N = 285), the median age was
79 years (Interquartile range = 74–84) and the vast
majority were admitted from a home environment
(own home, children’s home, or social/sheltered
accommodation) (91%; N = 530) (Table 2). PwD
were significantly older, more dependent, and had
higher co-morbidities than those without dementia
(all p-values < 0.001). PwD were also significantly
more likely to be admitted from a nursing home, to
be acutely admitted to hospital, or to have delirium
on admission (all p-values ≤ 0.001). One-fifth (N
= 115) of all patients were diagnosed with delirium
at admission and PwD constituted the majority of
these cases (73%; N = 84).
Prescribing patterns
Six patients were taking no medication on
admission. PwD were prescribed almost one
medication more per patient, on average, than
those without dementia (mean ± standard
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N=676 non-day case admissions, ≥ 70 
years, eligible for trial (100%) 
Missed patients; untraceable or 
discharged prior to screening, n=11, 
(1.6%) 
N=665 had initial contact for screening 
(98.4%) 
Refused, n=52, (7.7%) 
Dying, n=7 (1.1%) 
N=606 screened for dementia (89.6%) Not possible to reach consensus on dementia diagnosis, n=8, (1.2%) 
N=598 diagnosis assigned (88.4%) 
 N=449 no dementia 
 N=149 dementia 
Missing medication data, n=15, 
(2.2%) 
 N=13 no dementia 
 N=2 dementia 
N=583 diagnosis assigned with linked 
medication data (86.2%) 
 N=436 no dementia 
 N=147 dementia 
Figure 1. Flow diagram of participant.
deviation = 7.9 ± 3.3 vs. 7.1 ± 3.6; T= −2.1;
p-value = 0.04) as shown in Table 3. However,
when corrected for age, sex, and co-morbidity, this
difference became non-significant (β = 0.3; 95%
CI = −0.4–1.0; p-value = 0.43). The prevalence
of polypharmacy was 84% in PwD and 77% in
people without dementia; however, this difference
was not significant (p = 0.08). Furthermore,
there was no significant difference between the
two groups in terms of the prevalence of major
polypharmacy (27% in PwD and 23% in people
without dementia; p-value = 0.35).
PwD were significantly more likely to be
prescribed at least one psychotropic medication
(χ2 = 28.9; aOR = 2.6, 95% CI = 1.7–
4.0; p-value < 0.001). Atypical anti-psychotics,
anti-depressants, anxiolytics, and anti-dementia
drugs were all significantly more likely to be
prescribed to PwD, even controlling for age, sex,
and co-morbidity (all p-values < 0.05). However,
there was no significant difference in hypnotic,
anti-convulsant/mood-stabilizer, or typical anti-
psychotic prescription between the two groups (all
p-values > 0.05). The prevalence of psychotropic
polypharmacy was 37% in PwD and 14% in
people without dementia and thus PwD were over
three times more likely to experience psychotropic
polypharmacy (χ2 = 35.9; aOR = 3.5; 95% CI
= 2.1–5.6; p-value < 0.001). Sensitivity analyses
found that even when we excluded anti-dementia
drugs and subsequently anti-convulsants/mood-
stabilizers from our definition of psychotropics,
PwD were still significantly more likely to be
prescribed at least one psychotropic (p-values ≤
0.002) and to be exposed to psychotropic poly-
pharmacy (p-values < 0.001) than those without
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Table 2. Demographics of study population
dementia no dementia total
(N = 147)a (N = 436)b (N= 583) p - value MWU/χ2
.........................................................................................................................................................................................................................................................................................................................
Sex, N (%)
Male 63 (42.3) 222 (50.9) 285 (48.9) 0.091 χ2 = 2.9
Age
Median 84 78 79 < 0.001∗ MWU = −8.2
IQR 79–89 74–82 74–84
Home type admitted from, N (%)
Home 113 (76.9) 417 (95.6) 530 (90.9) < 0.001∗∗ χ2 = 56.1
Nursing home 27 (18.4) 8 (1.8) 35 (6.0)
Sheltered
accommodation
7 (4.8) 11 (2.5) 18 (3.1)
CIRS-G score
Median 11 9 10 < 0.001∗ MWU = −4.1
IQR 8–15 7–12 7–13
Barthel index
Median 11 20 19 < 0.001∗ MWU = 12.7
IQR 6–17 17–20 14–20
Admission type, N (%)
Acute 120 (81.6) 300 (68.8) 420 (72.0) 0.003∗∗ χ2 = 9.0
Elective 27 (18.4) 136 (31.2) 163 (28.0)
Delirium on admission,
N (%)
84 (57.1) 31 (7.1) 115 (19.8) <0.001∗∗ χ2 = 173.4
aN = two dementia patients without completed medication data.
bN = 13 non-dementia patients without completed medication data.
∗Statistically significant at p-level < 0.05, utilizing MWU test.
∗∗Statistically significant at p-level < 0.05, utilizing χ2 test.
MWU = Mann–Whitney U test, CIRS-G = cumulative illness rating scale in geriatrics, IQR = inter-quartile range.
dementia (Table 3). Removing these two classes of
medications reduced the prevalence of psychotropic
polypharmacy in patients with and without demen-
tia to 29% versus 14% (excluding N06D), and then
to 24% versus 10% (excluding N06D and N03A)
respectively.
Looking at psychotropic medications in more
detail, 32% of PwD were prescribed anti-
depressants, compared to 19% of people without
dementia (χ2 = 10.1; aOR = 2.1; 95% CI = 1.3–
3.3; p-value = 0.002). Similarly, 14% of PwD (N
= 20) were prescribed at least one anti-psychotic,
compared to 5% of their peers (N = 21) (χ2
= 13.0; aOR = 3.7; 95% CI = 1.8–7.6; p-value
< 0.001). In terms of those who had a previous
diagnosis of dementia (N = 53), 28% (N = 15)
were prescribed an anti-psychotic, compared to just
5% (N = 5) of those who had no prior diagnosis
or a diagnosis of cognitive impairment (N = 94).
Patients admitted from nursing homes were almost
five times more likely to be prescribed an anti-
psychotic than those who were admitted from home
controlling for dementia diagnosis, age, sex, and co-
morbidity (χ2 = 26.7; aOR = 4.8; 95% CI = 1.9–
12.1; p-value = 0.001). Atypical anti-psychotics
(N = 30) were more commonly prescribed than
typical anti-psychotics (N = 14), predominantly
quetiapine (N = 17), and olanzapine (N = 11).
Just over half of all patients were prescribed
≥1 potentially deliriogenic medication (54%), with
no differences in the level of prescribing of these
agents between the two groups (χ2 < 0.01;
aOR = 0.9; 95% CI = 0.6–1.4; p-value = 0.6).
Benzodiazepines and systemic anti-cholinergics
were significantly more likely to be prescribed to
PwD (both p-value < 0.05), but differences became
non-significant after adjusting for age, sex, and co-
morbidity (both p-value > 0.05).
The four most commonly prescribed WHO
ATC anatomical groups were (i) cardiovascular
system, (ii) blood and blood forming organs, (iii)
alimentary tract and metabolism, and (iv) nervous
system, prescribed to 87%, 70%, 70%, and 60%
of all patients, respectively (see Table S1 published
as supplementary material online attached to the
electronic version of this paper at www.journals.
cambridge.org/jid_IPG). There were no differences
in the level of prescribing of any of the 13 included
WHO-ATC anatomical groups (all p-values >
0.05), except for nervous system drugs, which were
more commonly prescribed to PwD (χ2 = 19.6;
aOR = 2.0, 95% CI = 1.3–3.2; p-value = 0.003).
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Table 3. Prescribing patterns in hospitalized patients with and without dementia
no t-value , χ2 controlling for
dementia dementia total or fishers age , sex, and
(N = 147) (N= 436) (N= 583) p - value e exact test co-morbidity f
...........................................................................................................................................................................................................................................................................................................................................................................................................................................................
Total number of medications prescribed 1154 3117 4271 – – –
Number of patients prescribed ≥ 1
medication, N (%)
147 (100) 430 (98.6) 577 (99.0) 0.15 χ2 = 1.1 aOR = 0.9,
95% CI = 0.1–4.7
Number of medications per patient
Mean 7.9 7.1 7.3 0.04* T = −2.1 β = 0.3,
95% CI = −0.4–1.0
SD 3.3 3.6 3.5
Range 1–17 0–20 0–20
Number of patients who experienced the following levels of polypharmacy, N (%):
Minor polypharmacy (5–9 medications) 83 (56.5) 233 (53.4) 316 (54.2) 0.53 χ2 = 0.4 aOR = 1.0,
95% CI = 0.7–1.6
Major polypharmacy (≥ 10 medications) 40 (27.2) 102 (23.4) 142 (24.4) 0.35 χ2 = 0.9 aOR = 1.0,
95% CI = 0.6–1.6
Any polypharmacy (≥ 5 medications) 123 (83.7) 335 (76.8) 458 (78.6) 0.08 χ2 = 3.1 aOR = 1.1,
95% CI = 0.6–1.9
Number of patients prescribed ≥ 1 of the following psychotropic medications, N (%)
Anti-psychotics 20 (13.6) 21 (4.8) 41 (7.0) <0.001** χ2 = 13.0 aOR = 3.7,
95% CI = 1.8–7.6ǂ
Typical anti-psychotics 5 (3.4) 9 (2.1) 14 (2.4) 0.36 χ2 = 0.8 aOR = 1.6,
95% CI = 0.5–5.5
Atypical anti-psychotics 16 (10.9) 13 (3.0) 29 (5.0) <0.001** χ2 = 14.5 aOR = 4.7,
95% CI = 2.0–10.9ǂ
Anti-depressants 47 (32.0) 84 (19.3) 131 (22.5) 0.001** χ2 = 10.1 aOR = 2.1,
95% CI = 1.3–3.3ǂ
Anxiolytics 21 (14.3) 27 (6.2) 48 (8.2) 0.002** χ2 = 9.5 aOR = 2.3,
95% CI = 1.2–4.6ǂ
Hypnotics 29 (19.7) 74 (17.0) 103 (17.7) 0.45 χ2 = 0.6 aOR = 0.9,
95% CI = 0.5–1.5
Anti-convulsants/mood-stabilizer 16 (10.9) 50 (11.5) 66 (11.4) 0.85 χ2 = 0.03 aOR = 0.9,
95% CI = 0.5–1.7
Anti-dementia drugs 35 (23.8) 3 (0.7) 38 (6.5) <0.001** F < 0.001 aOR = 47.9, 95% CI =
13.8–166.3ǂ
Any psychotropic medicationa 99 (67.4) 182 (41.7) 281 (48.2) <0.001** χ2 = 28.9 aOR = 2.6,
95% CI = 1.7–4.0ǂ
Any psychotropic medication
(excluding anti-dementia dugs)
83 (56.5) 182 (41.7) 265 (45.5) 0.002** χ2 = 9.6 aOR = 1.6,
95% CI = 1.1–2.4ǂ
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Table 3. Continued.
no t-value , χ2 controlling for
dementia dementia total or fishers age , sex, and
(N = 147) (N= 436) (N= 583) p - value e exact test co-morbidity f
...........................................................................................................................................................................................................................................................................................................................................................................................................................................................
Any psychotropic medication
(excluding anti-dementia drugs and
anti-convulsants/mood-stabilizers)
75 (51.0) 155 (35.6) 230 (39.5) 0.001** χ2 = 11.0 aOR = 1.7,
95% CI = 1.1–2.5ǂ
Number of patients who experienced the following levels of psychotropic prescribing, N (%)
No psychotropic medication
prescribeda
48 (32.7) 254 (58.3) 302 (51.8) <0.001** χ2 = 28.9 aOR = 0.4,
95% CI = 0.2–0.6ǂ
Only one psychotropic medication
prescribeda
45 (30.6) 121 (27.8) 166 (28.5) 0.5 χ2 = 0.4 aOR = 1.0,
95% CI = 0.6–1.6
Psychotropic Polypharmacya
(≥ 2 psychotropics)
54 (36.7) 61 (14.0) 115 (19.7) <0.001** χ2 = 35.9 aOR = 3.5,
95% CI = 2.1–5.6ǂ
Psychotropic Polypharmacy
(≥ 2 psychotropics) (excluding
anti-dementia dugs)
43 (29.3) 60 (13.8) 103 (17.7) <0.001** χ2 = 18.1 aOR = 2.5,
95% CI = 1.5–4.1ǂ
Psychotropic polypharmacy
(≥ 2 psychotropics) (excluding
anti-dementia dugs and
anti-convulsants/mood stabilizers)
35 (23.8) 44 (10.1) 79 (13.6) <0.001** χ2 = 17.7 aOR = 2.7,
95% CI = 1.5–4.6ǂ
Number of patients prescribed ≥ 1 of the following potentially deliriogenic medicationb, N (%)
Benzodiazepines 32 (21.8) 52 (11.3) 84 (14.4) 0.003** χ2 = 8.6 aOR = 1.7,
95% CI = 0.9–2.9
Opioids 18 (12.2) 78 (17.9) 96 (16.5) 0.11 χ2 = 2.5 aOR = 0.7,
95% CI = 0.4–1.3
Dihydropyridines 18 (12.2) 72 (16.5) 90 (15.4) 0.22 χ2 = 1.5 aOR = 0.8,
95% CI = 0.4–1.4
Tricyclic anti-depressants 9 (6.1) 17 (3.9) 26 (4.5) 0.26 χ2 = 1.3 aOR = 1.5,
95% CI = 0.6–3.6
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Table 3. Continued.
no t-value , χ2 controlling for
dementia dementia total or fishers age , sex, and
(N = 147) (N= 436) (N= 583) p - value e exact test co-morbidity f
...........................................................................................................................................................................................................................................................................................................................................................................................................................................................
Systemic anti-cholinergicsc 23 (15.7) 42 (9.6) 65 (11.2) 0.045** χ2 = 4.0 aOR = 1.5,
95% CI = 0.8–2.8
Systemic steroids 7 (4.8) 40 (9.2) 47 (8.1) 0.09 χ2 = 2.9 aOR = 0.4,
95% CI = 0.1–0.9^
H2-receptor antagonists 2 (1.4) 2 (0.5) 4 (0.7) 0.27 F = 0.27 aOR = 2.5,
95% CI = 0.3–23.4
Anti-Parkinson’s drugs 6 (4.1) 9 (2.1) 15 (2.6) 0.18 χ2 = 1.8 aOR = 2.0,
95% CI = 0.6–6.4
Benzodiazepine-related drugs 14 (9.5) 46 (10.6) 60 (10.3) 0.72 χ2 = 0.1 aOR = 0.7,
95% CI = 0.4–1.4
Any potentially deliriogenic drug 79 (53.7) 235 (53.9) 314 (53.9) 0.97 χ2 < 0.01 aOR = 0.9,
95% CI = 0.6–1.4
Systemic NSAIDd 5 (3.4) 29 (6.7) 34 (5.8) 0.15 χ2 = 2.1 aOR = 0.5,
95% CI = 0.2–1.5
aPsychotropic defined as anti-psychotics, anti-depressants, anxiolytic, hypnotics, anti-convulsants/mood-stabilizer, and anti-dementia drugs.
bDeliriogenic medications defined by group consensus a priori.
cSystemic anti-cholinergics defined by group consensus a priori.
dSystemic non-steroidal anti-inflammatory drugs not included in the potentially deliriogenic drug category, but shown here for illustration purposes.
ep-value for two-way table with measures of association.
fAdjusted odds ratio for dependent variable utilizing linear or logistic regression as appropriate, with age, sex, and CIRS-G as the independent variables.
∗Statistically significant at p-level < 0.05, utilizing Student’s t-test.
∗∗Statistically significant at p-level < 0.05, utilizing χ2 test or Fishers exact test.
ǂStatistically significant at p-level < 0.05, utilizing logistic regression.
^Although significant at p-level < 0.05, this variable does not contain a minimum of ten cases of event and no event that are usually required for logistic regression analysis, therefore the findings
should not be interpreted as statistically significant.
CIRS-G = Cumulative Illness Rating Scale in Geriatrics, aOR = adjusted odds ratio, NSAID = Non-steroid anti-inflammatory drug, β = beta- coefficient, 95% CI = 95% confidence interval.
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Discussion
Main findings
This retrospective cross-sectional study aimed to
explore the prescribing patterns of psychotropic,
anti-cholinergic, and deliriogenic medications, and
polypharmacy, in a well-defined cohort of hospit-
alized older Irish patients; and to assess whether
having dementia influenced these prescribing
patterns. Overall, we found that this population was
prescribed high levels of medication, with over two-
thirds experiencing polypharmacy and a quarter
experiencing major polypharmacy. PwD were more
likely to be prescribed psychotropic medications
and to experience psychotropic polypharmacy. We
found no differences in the prescribing patterns in
terms of number of medications, anti-cholinergic
medications, deliriogenic medications, or any of the
other main WHO ATC anatomical groups, except
for nervous system medications.
Another important finding of the Cork De-
mentia Study was that only 35.5% of PwD had
an explicit diagnosis of dementia prior to the
study. Previous studies conducted in Australia
(Travers et al., 2013) and the UK (Sampson et al.,
2009) reported similar levels of under-diagnosis
in PwD requiring an admission to hospital. This
low rate of diagnosis may result in inappropriate
medications being prescribed to PwD and hospital
physicians incorrectly assuming capacity to consent
for complex treatments (Timmons et al., 2015).
Our results are in agreement with several
pharmacoepidemiological studies, which found a
high prevalence of psychotropic medicine use
in older hospitalized patients in general (Vidal
et al., 2016), and significantly higher levels of
psychotropic medications being prescribed to PwD
than to those without dementia (Wills et al.,
1997; Hartikainen et al., 2003; Hosia-Randell and
Pitkälä, 2005; Wergeland et al., 2014). These
findings are not surprising due to the ubiquity
of BPSD in dementia. One large scale study
of the longitudinal course of BPSD in PwD
reported a five-year period prevalence of BPSD
symptoms of 97% (Steinberg et al., 2008). The
most commonly reported symptoms were apathy,
depression, and delusions. Of note in this study,
many PwD already had BPSD at the time of
initial dementia diagnosis. Furthermore, many
studies have reported the presence of BPSD
in Mild Cognitive Impairment (MCI) (Mariani
et al., 2007). There are very recently published
criteria for diagnosing Mild Behavioral Impairment
(MBI) (Ismail et al., 2016) that describe BPSD
as a possible index manifestation of dementia,
in advance of measurable cognitive impairment.
This is an important conceptual advance in our
understanding of dementia, and the prescription of
psychotropic medications for changes in behavior
or personality may give an indication of an
emergent dementia. Furthermore, benzodiazepines
are often associated with cognitive decline and
dementia (Billioti de Gage et al., 2012); with the
implication of causality between the two, although
a recent study has questioned this causal association
(Gray et al., 2016). An alternative hypothesis is
that anxiety can present as the index manifestation
of dementia, with benzodiazepines prescribed, and
when the underlying dementia ultimately declares
itself, the benzodiazepine is labeled as the culprit
for cognitive decline (Ismail et al., 2016). The
bottom line is that BPSD are fundamental and core
features of dementia, and result in greater illness
burden, higher caregiver burden, poorer quality
of life, higher rates of institutionalization, faster
cognitive decline and death, and are associated with
greater plaque and tangle burden (Tekin et al.,
2001; Shin et al., 2005; Steinberg et al., 2008).
Notwithstanding these important contextual
issues, the fact remains that PwD are often
excessively and inappropriately prescribed psycho-
tropic medications, and for prolonged periods of
time (Banerjee, 2009). We know that in PwD,
anti-psychotics significantly increase the risk of
stroke and mortality (Maust et al., 2015) and
benzodiazepines significantly increase the risk of
falls and hip fractures (Hartikainen et al., 2007).
Prescription of multiple psychotropic agents results
in even greater risk of adverse events (Mojtabai
and Olfson, 2010). It is imperative that prescribers
and care providers adhere to guidelines, in so
far as possible, by utilizing non-pharmacological
interventions in the first instance and prescribing
anti-psychotics as a last resort, with regular review
and trials of withdrawal (Azermai et al., 2012).
There is evidence to support the use of non-
pharmacological interventions in managing BPSD
(Cabrera et al., 2015); however, better quality trials
are required in this area.
The prevalence of anti-psychotic usage in the
pharmacoepidemiological studies mentioned above
ranged from 5% to 43% in those with dementia,
highest in studies looking at institutionalized
patients. In comparison, the prevalence of anti-
psychotic usage in PwD in our study, where 91% of
patients were admitted from a home environment,
was 14%, lower than a previous study of home-
dwelling older people (33%) (Hartikainen et al.,
2003). This probably reflects the high rate of
undiagnosed cases in our study, with only 35.5%
having a prior diagnosis. The rates of prescribing
in our study population with known dementia
was 28%, similar to that found in the study by
Hartikainen et al. The INAD study conducted in
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2013 found that 41% of PwD were prescribed
anti-psychotic medications during their admission
in Irish hospitals, and also found poor levels of
documentation of mental health assessment and
drug indication (de Siún et al., 2014; Gallagher
et al., 2016). This figure is much higher than
what we found in our study, and may reflect the
purposeful selection of patients for the audit who
had an explicit diagnosis of dementia and a longer
length of stay, thereby potentially representing a
much frailer sub-population of PwD. Nonetheless,
this high figure is still alarming, considering the
same audit conducted in England and Wales in
2012–2013 (Royal College of Psychiatrists, 2013)
and Northern Ireland in 2014–2015 (O’Shea et al.,
2015) found much lower levels of anti-psychotic
prescribing; 18% and 21%, respectively.
We found that patients admitted from a nursing
home (N= 35) were almost five times more likely to
be prescribed an anti-psychotic than those admitted
from other home types. The INAD report also
found that PwD admitted from nursing homes were
significantly more likely to be prescribed an anti-
psychotic compared to those admitted from their
own home (46% vs. 19%; p < 0.001) (de Siún
et al., 2014; Gallagher et al., 2016). Similarly, a
cross-sectional Finnish nursing home population
study found that 43% of residents were prescribed
anti-psychotics (Hosia-Randell and Pitkälä, 2005).
These findings would indicate that in a busy
hospital setting, pharmacists and other healthcare
professionals should prioritize PwD, along with
patients admitted from nursing homes, for review
of their anti-psychotic medications. However, a
recent systematic review concluded that there
is a distinct lack of such studies conducted in
hospitalized dementia patients (Walsh et al., 2016).
It is important that any anti-psychotic medication
review conducted in a hospital setting involves
effective communication with the patient’s General
Practitioner, carers, and nursing home staff, as it
is necessary to know the indication for the anti-
psychotic and whether any non-pharmacological
intervention or dose reduction had been previously
attempted (Mueller et al., 2012). It is also crucial
that these community-based care providers are
informed of any plans for dose titrations or
withdrawals at hospital discharge to prevent the
unintended re-commencement of these patients on
anti-psychotics.
We did not find any significant differences in
terms of anti-cholinergic, deliriogenic, or total
number of medications prescribed between the two
patient groups. We were surprised by the former
finding, as previous studies have reported higher
levels of anti-cholinergic prescribing in PwD (Roe
et al., 2002). One potential hypothesis is that a
greater level of awareness surrounding the risk of
cognitive decline with these agents has resulted
in more careful prescribing in PwD. However,
a repeated cross-sectional study conducted in
Scotland found that despite the increasing evidence
surrounding the adverse effects of anti-cholinergics,
exposure to these agents in the elderly has actually
increased in recent years (Sumukadas et al., 2013).
We were unable to find literature on the prevalence
of deliriogenic medication usage in PwD, thus
our a priori hypothesis on this topic was purely
speculative, based on the knowledge that the
PwD in the study had more co-morbidities than
their peers. Further research should be conducted
to investigate the consequences of deliriogenic
prescribing in PwD. The evidence on medication
burden in PwD is mixed, with some studies
finding PwD are prescribed more (Andersen et al.,
2011) and others finding they are prescribed less
medications (Schmader et al., 1998) than people
without dementia. The discrepancies may relate to
population differences between the studies.
Our results differ from previous findings in
that we did not detect any significant differences
in prescribing patterns of cardiovascular agents
between those with and without dementia, whereas
previous studies found that PwD were prescribed
significantly less of these agents (Wolf-Klein
et al., 1988; Wills et al., 1997). One study
found that PwD had less co-morbidities than
those without dementia (Wolf-Klein et al., 1988).
Another group suggested that people without
cardiovascular disease may live longer and thus
develop dementia without requiring cardiovascular
agents (Wills et al., 1997). Given the known links
between cerebrovascular disease and dementia,
we would suggest that reduced cardiovascular
medication prescribing may have resulted from
practitioners reducing non-essential medications,
such as statins, in older, frailer PwD, especially
in more advanced disease. Our cohort of PwD,
where 64.5% had no previous diagnosis, probably
reflects true prescribing rates without any bias
from prescriber’s dementia status knowledge. Our
analysis shows that drug use by patients with
and without dementia was relatively similar for
all groups of medications, once age, sex, and
co-morbidity were considered, except for nervous
system medications.
Strengths and limitations
The main strength of this research was the large
number of patients recruited into this multi-
centered trial and the vast amount of rich data
that were collected from each patient allowing us to
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tease apart effects of dementia from confounding
factors such as age, sex, and co-morbidity.
The main limitation of this study is due
to the retrospective nature of the medication
analysis, so that it was not possible to resolve
any ambiguous medication data entries. However,
the quality of data collection was quite high
and this ambiguity rarely occurred. Second, as
the study is observational, it is not possible to
draw any conclusions on causality, as dementia
or cognitive impairment may have been the cause
of or potentially even the result of differences
in medication usage between the two patient
groups. Third, the lack of information on strength,
quantity, and duration of medication usage is
a limitation to our study. It would have been
interesting to investigate the differences in dosing
within and between the two patient groups, as
toxicity with anti-psychotics, for example, is largely
dose-dependent (De Hert et al., 2012). Finally, as
the study was conducted in only one county in
Ireland, the findings may not be representative of
the entire older Irish population. However, as the
demographic profile of Cork County is relatively
similar to that of the rest of the country, we believe
these results may possibly be representative of the
entire older Irish population.
Conclusion
Psychotropic drug use and polypharmacy is
highly prevalent, and dementia is under-diagnosed
among older Irish hospitalized patients. PwD are
more likely to be prescribed anti-psychotics, anti-
depressants, anxiolytics, and anti-dementia drugs.
PwD are also more likely to be exposed to
psychotropic polypharmacy. These differences in
prescribing patterns may be largely attributed to
BPSD in dementia, and NPS in pre-dementia
clinical syndromes like MCI and MBI. Longitud-
inal research is required to assess the long-term
impact that medication usage or non-usage has
on the development of dementia in older people
and also to assess the impact that a diagnosis
of dementia has on the physician’s prescribing
patterns. High quality trials of multi-disciplinary
team medication reviews should be conducted in
the acute care setting, targeting older patients at
high risk of potentially inappropriate prescribing of
anti-psychotics, namely PwD and those admitted
from nursing homes.
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